COMPASS Pathways plc
CMPSHealthcareNASDAQMedical Care Facilities
Scan Results
Daily timeframePart of the healthcare sector, COMPASS Pathways plc (CMPS) is listed under Medical Care Facilities. Valued at $1.67B, CMPS is a small-cap name in its sector. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Market Cap
$1.67B
Beta
2.49
P/E (TTM)
—
P/E (Fwd)
-11.38
EPS (TTM)
$-3.12
EPS (Fwd)
$-1.08
ROE
-68.5%
ROA
-25.6%
Cash
$466.0M
Total Debt
$53.3M
Free CF
$33.1M
52W Change
187.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $466.0M in cash comfortably exceeding the $53.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $33.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -68.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, CMPS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, CMPS has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for COMPASS Pathways plc and its sector.